Some years ago, Snapinn and Jiang[1] considered the interpretation and pitfalls of absolute versus relative treatment effect measures in analyses of time-to-event outcomes. Through specific examples and analytical considerations based solely on the exponential and the Weibull distributions they reach two conclusions: 1) that the commonly used criteria for clinical effectiveness, the ARR (Absolute Risk Reduction) and the median (survival time) difference (MD) directly contradict each other and 2) cost-effectiveness depends only the hazard ratio(HR) and the shape parameter (in the Weibull case) but not the overall baseline risk of the population. Though provocative, the first conclusion does not apply to either the two special cases considered or even more generally, while the second conclusion is strictly correct only for the exponential case. Therefore, the implication inferred by the authors i.e. all measures of absolute treatment effect are of little value compared with the relative measure of the hazard ratio, is not of general validity and hence both absolute and relative measures should continue to be used when appraising clinical evidence.
翻译:几年前,Snatinn和Jiang[1]在分析时间到活动结果时,考虑了绝对和相对处理效果措施的解释和陷阱。通过仅仅基于指数和韦布尔分布的具体例子和分析考虑,它们得出了两个结论:(1) 临床有效性的常用标准、ARR(绝对风险减少)和中位(生存时间)差异(MD)直接相互矛盾;(2) 成本效益仅取决于危害比率(HR)和形状参数(Weibull案),而不是人口的总体基线风险。尽管第一个结论具有挑衅性,但不适用于所审议的两个特殊案例,甚至更笼统地说,第二个结论严格地说,只适用于指数案例。因此,作者推断的绝对治疗效果的所有措施与危害比率的相对衡量相比,其价值不大,因此在评估临床证据时应继续采用绝对和相对措施。